Ma, Y.; Sender, S.; Sekora, A.; Kong, W.; Bauer, P.; Ameziane, N.; Krake, S.; Radefeldt, M.; Al-Ali, R.; Weiss, F.U.;
et al. Inhibitory Response to CK II Inhibitor Silmitasertib and CDKs Inhibitor Dinaciclib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines. Int. J. Mol. Sci. 2022, 23, 4409.
https://doi.org/10.3390/ijms23084409
AMA Style
Ma Y, Sender S, Sekora A, Kong W, Bauer P, Ameziane N, Krake S, Radefeldt M, Al-Ali R, Weiss FU,
et al. Inhibitory Response to CK II Inhibitor Silmitasertib and CDKs Inhibitor Dinaciclib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines. International Journal of Molecular Sciences. 2022; 23(8):4409.
https://doi.org/10.3390/ijms23084409
Chicago/Turabian Style
Ma, Yixuan, Sina Sender, Anett Sekora, Weibo Kong, Peter Bauer, Najim Ameziane, Susann Krake, Mandy Radefeldt, Ruslan Al-Ali, Frank Ulrich Weiss,
and et al. 2022. "Inhibitory Response to CK II Inhibitor Silmitasertib and CDKs Inhibitor Dinaciclib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines" International Journal of Molecular Sciences 23, no. 8: 4409.
https://doi.org/10.3390/ijms23084409
APA Style
Ma, Y., Sender, S., Sekora, A., Kong, W., Bauer, P., Ameziane, N., Krake, S., Radefeldt, M., Al-Ali, R., Weiss, F. U., Lerch, M. M., Parveen, A., Zechner, D., Junghanss, C., & Murua Escobar, H.
(2022). Inhibitory Response to CK II Inhibitor Silmitasertib and CDKs Inhibitor Dinaciclib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines. International Journal of Molecular Sciences, 23(8), 4409.
https://doi.org/10.3390/ijms23084409
